HK1207374A1 - Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b] - Google Patents

Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b]

Info

Publication number
HK1207374A1
HK1207374A1 HK15108047.9A HK15108047A HK1207374A1 HK 1207374 A1 HK1207374 A1 HK 1207374A1 HK 15108047 A HK15108047 A HK 15108047A HK 1207374 A1 HK1207374 A1 HK 1207374A1
Authority
HK
Hong Kong
Prior art keywords
imidazo
kinase inhibitor
pyridazine derivative
pyridazine
derivative
Prior art date
Application number
HK15108047.9A
Other languages
English (en)
Chinese (zh)
Inventor
Yasuyuki Takeda
Kenji Yoshikawa
Yoshiko Kagoshima
Yuko Yamamoto
Ryoichi Tanaka
Yuichi Tominaga
Masaki Kiga
Yoshito Hamada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1207374A1 publication Critical patent/HK1207374A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15108047.9A 2012-06-04 2015-08-19 Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b] HK1207374A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[1,2-b]ピリダジン誘導体

Publications (1)

Publication Number Publication Date
HK1207374A1 true HK1207374A1 (en) 2016-01-29

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108047.9A HK1207374A1 (en) 2012-06-04 2015-08-19 Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b]

Country Status (32)

Country Link
US (2) US9187489B2 (pt)
EP (1) EP2857404B1 (pt)
JP (1) JP5814467B2 (pt)
KR (1) KR101781255B1 (pt)
CN (1) CN104520300B (pt)
AU (1) AU2013272701B2 (pt)
BR (1) BR112014029851B1 (pt)
CA (1) CA2874819C (pt)
CO (1) CO7160119A2 (pt)
CY (1) CY1119607T1 (pt)
DK (1) DK2857404T3 (pt)
ES (1) ES2648228T3 (pt)
HK (1) HK1207374A1 (pt)
HR (1) HRP20171724T1 (pt)
HU (1) HUE037221T2 (pt)
IL (1) IL236075A (pt)
IN (1) IN2014MN02497A (pt)
LT (1) LT2857404T (pt)
MX (1) MX357021B (pt)
MY (1) MY170326A (pt)
NO (1) NO2857404T3 (pt)
NZ (1) NZ702574A (pt)
PH (1) PH12014502721A1 (pt)
PL (1) PL2857404T3 (pt)
PT (1) PT2857404T (pt)
RS (1) RS56625B1 (pt)
RU (1) RU2635917C2 (pt)
SG (1) SG11201408052WA (pt)
SI (1) SI2857404T1 (pt)
TW (1) TWI585088B (pt)
WO (1) WO2013183578A1 (pt)
ZA (1) ZA201408843B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
HUE057625T2 (hu) 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
EP2857398A4 (en) 2012-05-30 2015-11-11 Nippon Shinyaku Co Ltd AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL PRODUCT
EA031639B1 (ru) * 2014-03-27 2019-01-31 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-а]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ И 2,3-ДИГИДРО-1H-ИМИДАЗО[1,2-b]ПИРАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
WO2015144799A1 (en) 2014-03-27 2015-10-01 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS
WO2015164869A1 (en) * 2014-04-25 2015-10-29 Exelixis, Inc. Method of treating lung adenocarcinoma
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換4−ベンジル及び4−ベンゾイルピペリジン誘導体
JP6999424B2 (ja) 2015-06-18 2022-01-18 エイティナイン バイオ リミテッド 1,4-置換ピペリジン誘導体
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
MA44612A (fr) 2016-04-04 2019-02-13 Loxo Oncology Inc Méthodes de traitement de cancers pédiatriques
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー, インコーポレイテッド (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110418792B (zh) * 2017-03-14 2022-07-05 第一三共株式会社 制备3,6-二取代咪唑并[1,2-b]哒嗪衍生物的方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CA3224945A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
US20220081438A1 (en) 2018-12-19 2022-03-17 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020179859A1 (ja) * 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP7420403B2 (ja) * 2019-05-08 2024-01-23 ティーワイケー メディシンズ インコーポレーテッド キナーゼ阻害剤として使用される化合物およびその応用
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
EP4363420A1 (en) * 2021-07-01 2024-05-08 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115A (zh) * 2022-08-25 2022-10-18 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
DK1846394T3 (da) 2005-02-04 2012-01-16 Astrazeneca Ab Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
WO2007014707A1 (en) * 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
KR101546493B1 (ko) * 2006-11-06 2015-08-21 톨레로 파마수티컬스, 인크. 이미다조[1,2-b]피리다진 및 피라졸로[1,5-a]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
EP2350075B1 (en) * 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
AU2013272701B2 (en) 2017-12-21
CA2874819C (en) 2017-06-20
DK2857404T3 (en) 2017-12-04
ES2648228T3 (es) 2017-12-29
ZA201408843B (en) 2016-01-27
AU2013272701A1 (en) 2015-01-15
SI2857404T1 (sl) 2017-11-30
EP2857404A4 (en) 2016-01-20
NO2857404T3 (pt) 2018-01-20
LT2857404T (lt) 2017-11-10
CO7160119A2 (es) 2015-01-15
HUE037221T2 (hu) 2018-08-28
MY170326A (en) 2019-07-17
AU2013272701A2 (en) 2015-01-22
MX357021B (es) 2018-06-25
RU2014153627A (ru) 2016-08-10
BR112014029851A2 (pt) 2017-06-27
TWI585088B (zh) 2017-06-01
IN2014MN02497A (pt) 2015-07-17
RS56625B1 (sr) 2018-03-30
HRP20171724T1 (hr) 2018-01-12
KR20150014942A (ko) 2015-02-09
US20150051190A1 (en) 2015-02-19
PH12014502721B1 (en) 2015-02-02
WO2013183578A1 (ja) 2013-12-12
US9187489B2 (en) 2015-11-17
IL236075A (en) 2017-10-31
CN104520300A (zh) 2015-04-15
EP2857404B1 (en) 2017-08-23
JPWO2013183578A1 (ja) 2016-01-28
NZ702574A (en) 2016-07-29
MX2014014803A (es) 2015-02-12
PH12014502721A1 (en) 2015-02-02
CA2874819A1 (en) 2013-12-12
IL236075A0 (en) 2015-02-01
CY1119607T1 (el) 2018-04-04
KR101781255B1 (ko) 2017-09-22
US9751887B2 (en) 2017-09-05
EP2857404A1 (en) 2015-04-08
TW201400486A (zh) 2014-01-01
BR112014029851B1 (pt) 2023-01-03
RU2635917C2 (ru) 2017-11-17
PT2857404T (pt) 2017-11-23
SG11201408052WA (en) 2015-01-29
US20160046639A1 (en) 2016-02-18
JP5814467B2 (ja) 2015-11-17
PL2857404T3 (pl) 2018-04-30
CN104520300B (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
HK1207374A1 (en) Imidazo[1,2-b]pyridazine derivative as kinase inhibitor [12-b]
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
HK1185881A1 (zh) 取代的咪唑並 噠嗪
HK1212699A1 (zh) 作為 抑制劑的取代的咪唑並 噠嗪類化合物
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
PL2651417T3 (pl) Pochodne pirolopirymidyny hamujące ASK1
IL235819A0 (en) Preparation of pyrrolo[b–3,2]pyridines
ZA201409136B (en) Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimides as lrrk2 inhibitors
IL243092A0 (en) New triazolo[d–4,5]pyrimidine histories
HK1208678A1 (en) 3,5-diaminopyrazole kinase inhibitors 35-
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
HK1201830A1 (en) Substituted imidazopyrazines as akt kinase inhibitors akt
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
HK1206354A1 (en) Pyrrolo[2,3-b]pyrazines as syk inhibitors syk [23-b]
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
EP2523552A4 (en) PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
HK1201824A1 (en) Triazolopyridine derivatives as a tyrosine kinase inhibitor
HK1201831A1 (en) Substituted pyrazolopyrimidines as akt kinase inhibitors akt
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE FILING DATE OF THE PRIORITY APPLICATION